06 Feb
  • By Matter Now
  • Cause in

NS Pharma Community Letter

We are excited that our industry partner, NS Pharma, has applied for accelertated approval for it’s exon 53 skipping therapy, viltolarsen. We applaud the dedication to the Duchenne community by NS Pharma and look forward to continued success. NS Pharma Community Letter

READ MORE